Newsletter Archive

  1. 09.23.26 -- What Strong Biotech IP Strategies Get Right And Where Weak Ones Break Down 9/23/2026

    09/23/26 Life Science Leader Newsletter

  2. 09.21.26 -- Should R&D Be Organized Around The Therapy, Not The Drug? 9/21/2026

    09/21/26 Life Science Leader Newsletter

  3. 09.18.26 -- When Should R&D Turn Back? 9/18/2026

    09/18/26 Life Science Leader Newsletter

  4. 09.17.26 -- Your Collaborator: mAb Productivity And Robustness 9/17/2026

    09/17/26 Life Science Leader Newsletter

  5. 09.16.26 -- Picking Biotech Winners Beyond The Hype With Olivier Litzka 9/16/2026

    09/16/26 Life Science Leader Newsletter

  6. 09.15.26 -- Smarter Ways To Reduce Risk, Downtime, And Lifecycle Surprises 9/15/2026

    09/15/26 Life Science Leader Newsletter

  7. 09.14.26 -- Humacyte To Begin Testing Bioengineered Blood Vessel In Heart Bypass Surgery 9/14/2026

    09/14/26 Life Science Leader Newsletter

  8. 09.12.26 -- Life Science Leader Newsletter - Best Of August 9/12/2026

    09/12/26 Life Science Leader Newsletter

  9. 09.11.26 -- Investigator Perspectives On What Matters In Obesity And GLP-1 Studies 9/11/2026

    09/11/26 Life Science Leader Newsletter

  10. 09.10.26 -- Solving The Complexities of Rare Disease Clinical Development 9/10/2026

    09/10/26 Life Science Leader Newsletter